Evaluating the effect of low dose vs moderate dose clofibrate on decreasing serum bilirubin in healthy full term neonates
Phase 3
- Conditions
- eonatal jaundice.P59.9 Neonatal jaundice, unspecified
- Registration Number
- IRCT2012092910933N1
- Lead Sponsor
- Hamadan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 132
Inclusion Criteria
Inclusion criteria included: (a) age of 2 to 29 days; (b) full term newborn (gestational age between 38 to 40 weeks); (c) weight of 2500 to 4000 gr; having indirect hyperbilirubinemia (TSB>16 mg/dl) ; (d) absence of hemolysis, ABO or Rh incompatibility; (e) negative coomb’s test; (f) reticulocyte count less than 5%.
Exclusion criteria : The neonates with sign of sepsis, electrolyte impairment, any congenital anomalies or disease, seizure, formula feeding, hemolytic disease and those who need exchange transfusion were excluded from the study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bilirubin. Timepoint: Total and indirect bilirubin levels were measured at the beginning of treatment and then 12, 24, 36 and 48 hours later. Method of measurement: RA1000 Techinca.
- Secondary Outcome Measures
Name Time Method Bilirubin. Timepoint: Total and indirect bilirubin levels were measured at the beginning of treatment and then 12, 24, 36 and 48 hours later. Method of measurement: RA1000 Techinca.